CYFRA21-1 as a tumor marker in patients with malignant head and neck tumor

Teruhiro Ogawa; Kazunori Nishizaki; Hirohumi Akagi; Hirokazu Tsurusako; Keiko Nishioka; Kazunari Oda; Nobuhiko Kimura

doi:10.5631/jibirin.89.725

CYFRA21-1 as a tumor marker in patients with malignant head and neck tumor

Teruhiro Ogawa, Kazunori Nishizaki, Hirohumi Akagi, Hirokazu Tsurusako, Keiko Nishioka, Kazunari Oda, Nobuhiko Kimura

Graduate School of Medicine Dentistry and Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

It is well known that cytokeratin 19 is particularly abundant in squamous cell carcinoma of the lung. CYFRA21-1 was developed to detect soluble cytokeratin 19 fragment in serum using two specific monoclonal antibodies. We investigated the usefulness of this new marker compared with that of carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) using 52 serum samples from patients with head and neck malignancies. Of 50 cases of head and neck carcinomas, CYFRA21-1 was positive (>2.0ng/ml) in 21 cases (42.0%) while SCC was found in 9 cases and CEA in 8 cases. Therefore CYFRA21-1 was proven to be a more useful tumor marker than SCC or CEA. We analyzed the results statistically, and found that age and site of lesion (larynx) were factors affecting CYFRA21-1 concentration. The serum CYFRA21-1 level was also demonstrated to be independent of the other two markers. However, we could not determine the cut-off level of serum CYFRA21-1.

Original language	English
Pages (from-to)	725-730
Number of pages	6
Journal	Practica Otologica
Volume	89
Issue number	6
DOIs	https://doi.org/10.5631/jibirin.89.725
Publication status	Published - 1996

Keywords

CEA
CYFRA21-1
Head and neck malignancies
SCC
Tumor marker

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.5631/jibirin.89.725

Cite this

@article{d8185e9447cc4b1eb5c1d412206a297e,

title = "CYFRA21-1 as a tumor marker in patients with malignant head and neck tumor",

abstract = "It is well known that cytokeratin 19 is particularly abundant in squamous cell carcinoma of the lung. CYFRA21-1 was developed to detect soluble cytokeratin 19 fragment in serum using two specific monoclonal antibodies. We investigated the usefulness of this new marker compared with that of carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) using 52 serum samples from patients with head and neck malignancies. Of 50 cases of head and neck carcinomas, CYFRA21-1 was positive (>2.0ng/ml) in 21 cases (42.0%) while SCC was found in 9 cases and CEA in 8 cases. Therefore CYFRA21-1 was proven to be a more useful tumor marker than SCC or CEA. We analyzed the results statistically, and found that age and site of lesion (larynx) were factors affecting CYFRA21-1 concentration. The serum CYFRA21-1 level was also demonstrated to be independent of the other two markers. However, we could not determine the cut-off level of serum CYFRA21-1.",

keywords = "CEA, CYFRA21-1, Head and neck malignancies, SCC, Tumor marker",

author = "Teruhiro Ogawa and Kazunori Nishizaki and Hirohumi Akagi and Hirokazu Tsurusako and Keiko Nishioka and Kazunari Oda and Nobuhiko Kimura",

year = "1996",

doi = "10.5631/jibirin.89.725",

language = "English",

volume = "89",

pages = "725--730",

journal = "Practica Otologica",

issn = "0032-6313",

publisher = "Society of Practical Otolaryngology",

number = "6",

}

TY - JOUR

T1 - CYFRA21-1 as a tumor marker in patients with malignant head and neck tumor

AU - Ogawa, Teruhiro

AU - Nishizaki, Kazunori

AU - Akagi, Hirohumi

AU - Tsurusako, Hirokazu

AU - Nishioka, Keiko

AU - Oda, Kazunari

AU - Kimura, Nobuhiko

PY - 1996

Y1 - 1996

N2 - It is well known that cytokeratin 19 is particularly abundant in squamous cell carcinoma of the lung. CYFRA21-1 was developed to detect soluble cytokeratin 19 fragment in serum using two specific monoclonal antibodies. We investigated the usefulness of this new marker compared with that of carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) using 52 serum samples from patients with head and neck malignancies. Of 50 cases of head and neck carcinomas, CYFRA21-1 was positive (>2.0ng/ml) in 21 cases (42.0%) while SCC was found in 9 cases and CEA in 8 cases. Therefore CYFRA21-1 was proven to be a more useful tumor marker than SCC or CEA. We analyzed the results statistically, and found that age and site of lesion (larynx) were factors affecting CYFRA21-1 concentration. The serum CYFRA21-1 level was also demonstrated to be independent of the other two markers. However, we could not determine the cut-off level of serum CYFRA21-1.

AB - It is well known that cytokeratin 19 is particularly abundant in squamous cell carcinoma of the lung. CYFRA21-1 was developed to detect soluble cytokeratin 19 fragment in serum using two specific monoclonal antibodies. We investigated the usefulness of this new marker compared with that of carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) using 52 serum samples from patients with head and neck malignancies. Of 50 cases of head and neck carcinomas, CYFRA21-1 was positive (>2.0ng/ml) in 21 cases (42.0%) while SCC was found in 9 cases and CEA in 8 cases. Therefore CYFRA21-1 was proven to be a more useful tumor marker than SCC or CEA. We analyzed the results statistically, and found that age and site of lesion (larynx) were factors affecting CYFRA21-1 concentration. The serum CYFRA21-1 level was also demonstrated to be independent of the other two markers. However, we could not determine the cut-off level of serum CYFRA21-1.

KW - CEA

KW - CYFRA21-1

KW - Head and neck malignancies

KW - SCC

KW - Tumor marker

UR - http://www.scopus.com/inward/record.url?scp=29344454921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29344454921&partnerID=8YFLogxK

U2 - 10.5631/jibirin.89.725

DO - 10.5631/jibirin.89.725

M3 - Article

AN - SCOPUS:29344454921

SN - 0032-6313

VL - 89

SP - 725

EP - 730

JO - Practica Otologica

JF - Practica Otologica

IS - 6

ER -

CYFRA21-1 as a tumor marker in patients with malignant head and neck tumor

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this